Research programme: eye disorder therapies - Bicycle Therapeutics/ThromboGenics

Drug Profile

Research programme: eye disorder therapies - Bicycle Therapeutics/ThromboGenics

Alternative Names: TG-758; THR 149

Latest Information Update: 16 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bicycle Therapeutics
  • Developer Bicycle Therapeutics; ThromboGenics
  • Class Peptides
  • Mechanism of Action Capillary permeability modulators; Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Eye-Disorders

Most Recent Events

  • 16 Mar 2017 ThromboGenics plans a phase I trial of THR 149 for Diabetic macular oedema in first half of 2018
  • 16 Oct 2014 Preclinical development is ongoing in United Kingdom & Belgium
  • 05 Sep 2013 Preclinical trials in Diabetic macular oedema in Belgium (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top